Federated Hermes’s Celldex Therapeutics CLDX Stock Holding History

Federated Hermes’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.3M	Buy	+492,893	New	+$15.9M	0.03%	521
2021 Q4	–	Sell	-121	Closed	-$7K	–	2214
2021 Q3	$7K	Buy	+121	New	+$5.68K	﹤0.01%	2016
2021 Q1	–	Sell	-114	Closed	-$2K	–	2243
2020 Q4	$2K	Buy	114 +68	+148%	+$1.22K	﹤0.01%	2118
2020 Q3	$1K	Buy	+46	New	+$539	﹤0.01%	2143
2018 Q2	–	Sell	-1	Closed	-$1K	–	2208
2018 Q1	$1K	Sell	1 -6,054	-100%	-$235K	﹤0.01%	2091
2017 Q4	$258K	Sell	6,055 -564	-9%	-$24.2K	﹤0.01%	1477
2017 Q3	$284K	Sell	6,619 -4,021	-38%	-$151K	﹤0.01%	1452
2017 Q2	$394K	Sell	10,640 -27,820	-72%	-$1.23M	﹤0.01%	1429
2017 Q1	$2.08M	Buy	38,460 +3,211	+9%	+$167K	0.01%	895
2016 Q4	$1.87M	Buy	35,249 +5,091	+17%	+$290K	0.01%	897
2016 Q3	$1.83M	Buy	30,158 +4,164	+16%	+$259K	0.01%	884
2016 Q2	$1.71M	Buy	+25,994	New	+$1.65M	0.01%	904
2015 Q4	–	Sell	-7	Closed	-$1K	–	2096
2015 Q3	$1K	Buy	+7	New	+$1.98K	﹤0.01%	1894

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes's CLDX Position: Q2 2026 in Review

Federated Hermes opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 492,893 shares worth $18.3M. The stake represents 0.03% of the portfolio and ranks #521 among its holdings. This is a return to the name: Federated Hermes previously reported a position in CLDX as recently as Q3 2021.

Federated Hermes first reported a position in CLDX in Q3 2015 and has held it in 13 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Federated Hermes held 492,893 shares of Celldex Therapeutics worth $18.3M as of Q2 2026.
Celldex Therapeutics was a new Federated Hermes position in Q2 2026.
Celldex Therapeutics made up 0.03% of Federated Hermes's portfolio in Q2 2026, its #521 holding.
Federated Hermes first reported a position in Celldex Therapeutics in Q3 2015 and has held it in 13 quarters since.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.